阿德福韦酯联合胸腺肽α_1治疗慢性乙型肝炎临床观察

Adefovir dipivoxil and thymosin α_1 treatment of chronic hepatitis B clinical observation

目的:观察阿德福韦酯联合胸腺肽α1治疗慢性乙型肝炎的疗效。方法:将入选病例随机分为阿德福韦酯组和联合治疗组,阿德福韦酯组给予阿德福韦酯10mg.d-1,连续用48周;联合治疗组在阿德福韦酯组治疗的基础上加用胸腺肽α11.6mg,皮下注射,每周2次,连用48周。观察2组患者的生化应答率,病毒应答率,HBeAg阴转率。结果:阿德福韦酯组24周时生化应答率为56%,病毒应答率44%,HBeAg转阴率为13%;48周时生化应答率为72%,病毒应答率59%,HBeAg阴转率为41%。联合治疗组24周时生化应答率为87%,病毒应答率73%,HBeAg转阴率为40%;治疗48周时生化应答率为93%,病毒应答率87%,HBeAg阴转率为70%。结论:阿德福韦酯与胸腺肽α1联合治疗慢性乙型肝炎具有较好疗效。

OBJECTIVE To investigate the effectiveness of treatment of chronic hepatitis B by adefovir dipivoxil and combined with the thymosin α1 in combination. METHODS Cases were devided randomly into adefovir dipivoxil group and the joint treatment group. As to the conbination dipivoxil group, to inject adefovir dipivoxil 10 mg·d^-1 ,for 48 weeks; As to the joint treatment group, besides the adefovir dipivoxil group therapy, plus thymosin α1 1.6 mg, subcutaneous injection, twice a week, last out 48 weeks, To observe the two groups of patients with biochemical response rate, virus response rate, HBeAg negative rate. RESULTS Adefovir dipivoxil group： 24 weeks later, biochemical response rate was 56%, virus response rate was 44 percent, HBeAg negative rate was 13% ; 48 weeks later, biochemical response rate was 72%, virus response rate was 59%, HBeAg negative rate was 41 percent. The ioint treatment group： 24 weeks later, biochemical response rate was 87%, virus response rate was 73%, HBeAg negative rate was 40% ; 48 weeks later, biochemical response rate was 93%, Virus response rate was 87%, HBeAg negative rate was 70%. CONCLUSION The effectiveness of treatment of chronic hepatitis B by adefovir dipivoxil is remarkable, and the efficacy continues improving with the time; if used with thymosin α1 together, there will be a more significant effect.